Purpose
Our Mission
To translate breakthrough Canadian discoveries into globally accessible medicines that save lives and strengthen Canada's biotechnology leadership.
Transforming Canadian Science into Global Medicines
Novel Platform Technology for Life-Threatening Diseases
Overview
JN Nova Pharma is a Canadian biotechnology company developing a first-in-class platform technology designed to address serious diseases with significant unmet medical needs, including acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF), Acute Kidney Injury (AKI), and emerging viral and radiation-induced lung injuries.
Our proprietary, globally protected technology has been developed through Canadian collaboration and conducted all necessary research and development and is advancing toward clinical studies. By combining world-class Canadian science, artificial intelligence, strategic clinical partnerships, and Canadian biomanufacturing, we are committed to accelerating the development of innovative therapies that improve patient outcomes worldwide.
Our Partners
Ambition
Our Vision
To become a global leader in enzyme-based therapeutics for respiratory, inflammatory, and critical care diseases while establishing Canada as a hub for advanced biopharmaceutical innovation.
Advancing Innovation Through
- First-in-class platform technology
- Globally protected intellectual property
- AI-enabled drug development
- Canadian clinical excellence
- Canadian biomanufacturing
- Global commercialization strategy